Dr Sven Deutschmann
Roche Diagnostics
Referent:innen
Dr Christoph Höppner
Eurofins Biopharma Product Testing
Nicole Klüh
Labor LS
Dr. Marja Claassen
MSD
Dr. Radhakrishna Tirumalai
MSD
Dr. Sebastian Thölken
Lonza
Dr Holger Kavermann
Roche Diagnostics
All times mentioned are CEST.
Zielsetzung
During this Live Online Training, the following contents and questions should be addressed by presentations and panel discussions. Considering that, panelists from the fields Non-Sterile Products, Sterile Products, Combination Products as well as biopharmaceutical APIs and HCT/Ps will on hand for the training.
Hintergrund
In their Pharmacopeial Forum 39(4) in 2014, the USP published the draft of chapter <1115> “Bioburden Control of Nonsterile Drug Substances and Products”. The document outlines a risk-based approach to the control of potential contamination in non-sterile product manufacturing.
But “bioburden” is not only a topic of non-sterile products. Annex 1 of the European GMP Guideline requires “The bioburden should be monitored before sterilisation. There should be working limits on contamination immediately before sterilisation, which are related to the efficiency of the method to be used. Bioburden assay should be performed on each batch for both aseptically filled product and terminally sterilised products.”
And last but not least, bioburden testing for medical devices made or used in the USA is governed by Title 21 of the Code of Federal Regulations and worldwide by ISO 11737.
The current developments determine us to address this topic in a special workshop session to look at this from various angles and provide you with information about the regulatory background and practical examples and strategies for bioburden control. Pharmacopoeial experts, representatives of pharmaceutical quality control and from testing laboratory will show you what are the challenges of the bioburden control strategy and how they implemented an adequate control in their companies.
But “bioburden” is not only a topic of non-sterile products. Annex 1 of the European GMP Guideline requires “The bioburden should be monitored before sterilisation. There should be working limits on contamination immediately before sterilisation, which are related to the efficiency of the method to be used. Bioburden assay should be performed on each batch for both aseptically filled product and terminally sterilised products.”
And last but not least, bioburden testing for medical devices made or used in the USA is governed by Title 21 of the Code of Federal Regulations and worldwide by ISO 11737.
The current developments determine us to address this topic in a special workshop session to look at this from various angles and provide you with information about the regulatory background and practical examples and strategies for bioburden control. Pharmacopoeial experts, representatives of pharmaceutical quality control and from testing laboratory will show you what are the challenges of the bioburden control strategy and how they implemented an adequate control in their companies.
Zielgruppe
This Live Online Training is of interest to professionals in microbiology from
- Pharmaceuticals and Biopharmaceutical Companies
- Academic Research Institutions
- Government Agencies
- Contract Service laboratories
who are involved in
- Research and Development
- Validation
- Microbiological QA and QC
Technical Requirements
We use WebEx for our live online training courses and webinars. At https://www.gmp-compliance.org/training/online-training-technical-information you will find all the information you need to participate in our trainings and you can check if your system meets the necessary requirements to participate. If the installation of browser extensions is not possible due to your rights in the IT system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and easy.
Programm
Gesamtes Programm als PDF herunterladen
General Information
- Bioburden control strategy dependent of the lifecycle phase of the product (so-called “Phase-appropriate control strategy”)
- Early clinical Phase
- Late clinical hase
- Commercial phase - Test for “specified microorganisms” and / or “objectionable microorganisms”?
- Raw materials
- In-process-control samples
- Drug substance
- Drug product
- Final product - Refresher on biofilms including case studies
- Biofilm biology
- How to recognize biofilms in bioburden Trends
- Lessons learned from a company
Testing
- Where is bioburden tested in processes?
- Predefinition of bioburden and / or endotoxins levels for raw materials
- Assessment of the presence / absence of “objectionable microorganisms” in your raw materials ?
- What are the methods in use ?
- TAMC
- TYMC
- MPN
- Any other bioburden testing method
- Rapid micro methods - Is it necessary to have a limited shelf life for bioburden samples?
- How to treat so called “missing bioburden” results ?
Limits
- Predefined bioburden and / or endotoxins levels for your upstream / fermentation processes (if applicable) and downstream processes or for the whole process
- What will be preferred? A two-tiered-control system (warning and alert level) or a three-tiered control system (warning and alert level AND rejection level)?
- Methodologies in use to define the limits, e.g.
- how many data points are required to define the limits
- philosophy for new processes / new manufacturing processes without having experience of process capabilities
Deviation Management
- Do you perform ID? If YES, when:
- Each Colony
- Only in case of an excursion of limits / level - What’s the preferred ID technique?
- Measures in case of an excursion of a Limit
USP <1115>, USP<1229.3> and USP <1119>
- Bioburden control of non-sterile drug substances and products – USP and industrial view
- Bioburden monitoring, USP<1229.3> applies to sterile products
- USP <1119>
Presentation list:
- European Regulations
- USP<1115> Bioburden Control of Non-Sterile Drug Substances and Products
- Refresher on biofilms including case studies
- Microbial Control Strategy for Biopharmaceutical Manufacturing
- Microbial Counts and Bioburden of Combination Products: Guidelines, Specifics and Case Studies
- Bioburden for Sterile Operations
- Bioburden Monitoring, USP<1229.3> applies to Sterile Products, USP <1119>
- Bioburden Testing of Modern Medicinal Products- Practical Experience of a Contract Lab
- Various types of bioburden testing
- Technical challenges: Non-Steriles up to ATMP
- Practical Examples - from classic Pharmaceutical Products to HCT/Ps - Minimizing the impact of bioburden and sterility testing on gene therapy batch yield
- Assessment of Bioburden Excursions in Non-Sterile Biologics Manufacturing Processes
Dieses Seminar/Webinar kann nicht gebucht werden. Alternative Termine für dieses Seminar/Webinar und ähnliche Veranstaltungen finden Sie in der Übersicht nach Thema..
Für viele Seminare und Webinare gibt es auch Aufzeichnungen, die Sie jederzeit bestellen und anschauen können. Diese Aufzeichnungen finden Sie in einer themensortierten Liste.
Oder senden Sie uns Ihre Anfrage einfach über das folgende Kontaktformular.
* auch unkompliziert per Kreditkarte bezahlbar
Weitere Termine vor Ort
Weitere Termine vor Ort nicht verfügbar
Weitere Termine online
Weitere Termine online nicht verfügbar
Aufzeichnung nicht verfügbar
This course is part of the GMP Certification Programme "ECA Certified Microbiological Laboratory Manager"
Haben Sie noch Fragen?
Wir stehen Ihnen für weitere Auskünfte gerne zur Verfügung.
E-Mail: info@concept-heidelberg.de
Teilnehmerstimmen
Seminarprogramm als PDF
Sonderkonditionen DB BahnTeilnehmerstimmen - das sagen andere über unsere Seminare:
